肝移植后代谢综合征及其防治的研究进展

doi:10.3969/j.issn.1009-976X.2022.02.016

摘要/Abstract

摘要： 肝移植（LT）被认为是终末期肝病、重型肝炎和晚期肝脏恶性肿瘤患者的唯一根治性选择。由于近几十年来围手术期护理、感染控制和免疫抑制药物的改善,肝移植受体的早期存活率取得了巨大进步,但移植后晚期（移植后5年以上）的存活率却没有提高,主要原因是恶性肿瘤和心血管并发症。代谢综合征（MS）即肥胖、高血压、血脂异常和高血糖,在移植受者中被诊断为肝移植术后代谢综合征（LTMS）,影响肝移植受者长期生存。代谢综合征的许多方面都是可以改变的。这篇综述目的是总结目前关于LTMS及其相关组分的知识并探讨其防治与管理策略,旨在提供实用的循序渐进指导。

关键词: 肝移植, 代谢综合征, 糖尿病, 肥胖, 高血压, 血脂异常, 免疫抑制

Abstract: Liver transplantation （LT） is considered to be the only radical option for patients with end-stage liver disease, severe hepatitis and advanced liver malignant tumor （primary）. Due to the improvement of perioperative nursing, infection control and immunosuppressive drugs in recent decades, the early survival rate of liver transplant recipients has made great progress, but the survival rate in the late stage after transplantation （more than 5 years after transplantation） has not improved. The main causes of late death are malignant tumors and cardiovascular complications. Metabolic syndrome, defined as obesity, hypertension, dyslipidemia and hyperglycemia, is diagnosed as LTMS （liver transplantation metabolic syndrome） after liver transplantation in transplant recipients, affecting long-term survival. Many aspects of metabolic syndrome can be changed. The purpose of this review is to summarize the current knowledge about LTMS and its related components and to explore its prevention and management strategies, in order to provide practical step-by-step guidance.

Key words: liver transplantation, metabolic syndrome, diabetes, obesity, hypertension, dyslipidemia, immunosuppression

中图分类号:

R657.3

叶少炜, 钱均霖, 胡泽民. 肝移植后代谢综合征及其防治的研究进展[J]. 岭南现代临床外科, 2022, 22(02): 199-204.

YE Shao-wei, QIAN Jun-lin, HU Ze-min. Research progress on metabolic syndrome and its prevention and treatment after liver transplantation[J]. Lingnan Modern Clinics In Surgery, 2022, 22(02): 199-204.

参考文献

[1] European Association for the Study of the Liver. EASLClinical Practice Guidelines: Liver transplantation[J]. J Hepatol, 2016,64(2): 433-485.
[2] Shen T, Zhuang L, Sun XD, et al.Expert consensus on management of metabolic disease in Chinese liver transplant recipients[J]. World J Gastroenterol, 2020,26(27): 3851-3864.
[3] Imai D, Yoshizumi T, Sakata K, et al.Long-term Outcomes and Risk Factors After Adult Living Donor Liver Transplantation[J]. Transplantation, 2018,102(9): e382-e391.
[4] Aravinthan AD, Bruni SG, Doyle AC, et al.Liver Transplantation is a preferable alternative to palliative therapy for selected patients with advanced hepatocellular carcinoma[J]. Ann Surg Oncol, 2017,24(7): 1843-1851.
[5] Watt KD, Pedersen RA, Kremers WK, et al.Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study[J]. Am J Transplant, 2010,10(6): 1420-1427.
[6] Becchetti C, Dirchwolf M, Banz V, et al.Medical management of metabolic and cardiovascular complications after liver transplantation[J]. World J Gastroenterol, 2020,26(18): 2138-2154.
[7] Plotogea O, Ilie M, Sandru V, et al.Cardiovascular and Metabolic Consequences of Liver Transplantation: A Review[J]. Medicina (Kaunas), 2019,55(8): 133-154.
[8] Alberti KG, Eckel RH, Grundy SM, et al.Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity[J]. Circulation, 2009,120(16): 1640-1645.
[9] 中华医学会糖尿病学分会代谢综合征研究协作组. 中华医学会糖尿病学分会关于代谢综合征的建议[J]. 中华糖尿病杂志, 2004,12(3): 156-161.
[10] Thoefner LB, Rostved AA, Pommergaard HC, et al.Risk factors for metabolic syndrome after liver transplantation: A systematic review and meta-analysis[J]. Transplant Rev (Orlando), 2018,32(1): 69-77.
[11] 付俊玲, 肖新华. 代谢综合征的定义和流行病学[J]. 临床内科杂志, 2018,35(1): 5-9.
[12] Mahbuba S, Mohsin F, Rahat F, et al.Descriptive epidemiology of metabolic syndrome among obese adolescent population[J]. Diabetes Metab Syndr, 2018,12(3): 369-374.
[13] Adams LA, Arauz O, Angus PW, et al.Additive impact of pre-liver transplant metabolic factors on survival post-liver transplant[J]. J Gastroenterol Hepatol, 2016,31(5): 1016-1024.
[14] Cholongitas E, Koukoufiki A, Pipili C, et al.Is everolimus linked to metabolic syndrome in liver transplant recipients?[J]. Indian J Gastroenterol, 2019,38(4): 348-355.
[15] Jimenez-Perez M, Gonzalez-Grande R, Omonte GE, et al.Metabolic complications in liver transplant recipients[J]. World J Gastroenterol, 2016,22(28): 6416-6423.
[16] 中国医师协会器官移植医师分会, 中华医学会器官移植学分会肝移植学组. 中国肝移植受者代谢病管理专家共识(2019版)[J]. 器官移植, 2020,11(1): 19-29.
[17] Krasnoff JB, Vintro AQ, Ascher NL, et al.A randomized trial of exercise and dietary counseling after liver transplantation[J]. Am J Transplant, 2006,6(8): 1896-1905.
[18] Rodriguez-Peralvarez M, Germani G, Darius T, et al.Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis[J]. Am J Transplant, 2012,12(10): 2797-2814.
[19] Di Cosmo S, Lusignani M, Manini M, et al.Prevalence and risk factors of overweight and obesity after liver transplantation: retrospective study at three years after transplantation[J]. Prof Inferm, 2018,71(1): 3-10.
[20] van Son J, Stam SP, Gomes-Neto AW, et al. Post-transplant obesity impacts long-term survival after liver transplantation[J]. Metabolism, 2020,106(2): 154204.
[21] Kasmi S, Artru F, Barbosa JV, et al.Increasing prevalence of obesity and diabetes among patients evaluated for liver transplantation in a Swiss tertiary referral center: a 10-year retrospective analysis[J]. Swiss Med Wkly, 2022,152(2): w30138.
[22] Ferreira SC, Penaforte F, Cardoso A, et al.Eating behaviour patterns are associated with excessive weight gain after liver transplantation[J]. J Hum Nutr Diet, 2019,32(6): 693-701.
[23] Tanaka S, Fujita K, Makimoto K, et al.Relationships of accelerometer-determined physical activity with obesity, hypertension, diabetes, dyslipidemia, and health-related quality of life in patients after liver transplantation[J]. Clin Transplant, 2020,34(12): e14117.
[24] Dobrindt EM, Allex L, Saipbaev A, et al.Association between obesity after liver transplantation and steatosis, inflammation, and fibrosis of the graft[J]. Clin Transplant, 2020,34(12): e14093.
[25] Ata N, Ayloo S, Tsung A, et al.Recipient obesity does not affect survival after deceased donor liver transplantation for hepatocellular carcinoma. A national retrospective cohort study in the United States[J]. HPB (Oxford), 2019,21(1): 67-76.
[26] Cassiman D, Roelants M, Vandenplas G, et al.Orlistat treatment is safe in overweight and obese liver transplant recipients: a prospective, open label trial[J]. Transpl Int, 2006,19(12): 1000-1005.
[27] O′Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial[J]. Lancet, 2018,392(10148): 637-649.
[28] Tsochatzis E, Coilly A, Nadalin S, et al.International Liver Transplantation Consensus Statement on End-stage Liver Disease Due to Nonalcoholic Steatohepatitis and Liver Transplantation[J]. Transplantation, 2019,103(1): 45-56.
[29] Shivaswamy V, Boerner B, Larsen J.Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes[J]. Endocr Rev, 2016,37(1): 37-61.
[30] Ling Q, Xu X, Wang B, et al.The Origin of New-Onset Diabetes After Liver Transplantation: Liver, Islets, or Gut?[J]. Transplantation, 2016,100(4): 808-813.
[31] Grancini V, Resi V, Palmieri E, et al.Management of diabetes mellitus in patients undergoing liver transplantation[J]. Pharmacol Res, 2019,141(12): 556-573.
[32] 俞浩, 贾俊君, 周燕飞, 等. 肝移植后代谢性并发症的回顾性研究[C]. 2016中国器官移植大会暨第三届中国器官移植医师年会, 南京, 2016.
[33] Bhat V, Tazari M, Watt KD, et al.New-Onset Diabetes and Preexisting Diabetes Are Associated With Comparable Reduction in Long-Term Survival After Liver Transplant: A Machine Learning Approach[J]. Mayo Clin Proc, 2018,93(12): 1794-1802.
[34] Wallia A, Schmidt K, Oakes DJ, et al.Glycemic Control Reduces Infections in Post-Liver Transplant Patients: Results of a Prospective, Randomized Study[J]. J Clin Endocrinol Metab, 2017,102(2): 451-459.
[35] Sharif A, Hecking M, de Vries AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions[J]. Am J Transplant, 2014,14(9): 1992-2000.
[36] Pelaez-Jaramillo MJ, Cardenas-Mojica AA, Gaete PV, et al.Post-Liver Transplantation Diabetes Mellitus: A Review of Relevance and Approach to Treatment[J]. Diabetes Ther, 2018,9(2): 521-543.
[37] Vanhove T, Remijsen Q, Kuypers D, et al.Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus[J]. Transplant Rev (Orlando), 2017,31(2): 69-77.
[38] Davidson J, Wilkinson A, Dantal J, et al.New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003[J]. Transplantation, 2003,75(10 Suppl): S3-S24.
[39] Martinez-Saldivar B, Prieto J, Berenguer M, et al.Control of blood pressure in liver transplant recipients[J]. Transplantation, 2012,93(10): 1031-1037.
[40] Lemos B O, Silva R, Silva R.Prevalence and time of development of systemic arterial hypertension in patients after liver transplantation[J]. Arq Gastroenterol, 2021,58(1): 77-81.
[41] Gojowy D, Adamczak M, Dudzicz S, et al.High Frequency of Arterial Hypertension in Patients After Liver Transplantation[J]. Transplant Proc, 2016,48(5): 1721-1724.
[42] Di Stefano C, Vanni E, Mirabella S, et al.Risk factors for arterial hypertension after liver transplantation[J]. J Am Soc Hypertens, 2018,12(3): 220-229.
[43] Tong MS, Chai HT, Liu WH, et al.Prevalence of hypertension after living-donor liver transplantation: a prospective study[J]. Transplant Proc, 2015,47(2): 445-450.
[44] Toshima T, Yoshizumi T, Inokuchi S, et al.Risk factors for the metabolic syndrome components of hypertension, diabetes mellitus, and dyslipidemia after living donor liver transplantation[J]. HPB (Oxford), 2020,22(4): 511-520.
[45] Martinez-Saldivar B, Prieto J, Berenguer M, et al.Control of blood pressure in liver transplant recipients[J]. Transplantation, 2012,93(10): 1031-1037.
[46] Howard G, Banach M, Cushman M, et al.Is blood pressure control for stroke prevention the correct goal? The lost opportunity of preventing hypertension[J]. Stroke, 2015,46(6): 1595-1600.
[47] Lentine KL, Costa SP, Weir MR, et al.Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientific statement from the American Heart Association and the American College of Cardiology Foundation[J]. J Am Coll Cardiol, 2012,60(5): 434-480.
[48] Ramos-Lopez O, Martinez-Lopez E, Roman S, et al.Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico[J]. World J Gastroenterol, 2015,21(41): 11552-11566.
[49] Huang HT, Zhang XY, Zhang C, et al.Predicting dyslipidemia after liver transplantation: A significant role of recipient metabolic inflammation profile[J]. World J Gastroenterol, 2020,26(19): 2374-2387.
[50] Sheiner PA, Magliocca JF, Bodian CA, et al.Long-term medical complications in patients surviving > or = 5 years after liver transplant[J]. Transplantation, 2000,69(5): 781-789.
[51] 中华医学会器官移植学分会. 中国实体器官移植受者血脂管理规范(2019版)[J]. 器官移植, 2019,10(2): 101-111.
[52] Husing A, Kabar I, Schmidt HH.Lipids in liver transplant recipients[J]. World J Gastroenterol, 2016,22(12): 3315-3324.
[53] Mach F, Baigent C, Catapano AL, et al.2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk[J]. Eur Heart J, 2020,41(1): 111-188.
[54] Dos SA, Guardia AC, Pereira TS, et al.Rhabdomyolysis as a clinical manifestation of association with ciprofibrate, sirolimus, cyclosporine, and pegylated interferon-alpha in liver-transplanted patients: a case report and literature review[J]. Transplant Proc, 2014,46(6): 1887-1888.
[55] Neal DA, Gimson AE, Gibbs P, et al.Beneficial effects of converting liver transplant recipients from cyclosporine to tacrolimus on blood pressure, serum lipids, and weight[J]. Liver Transpl, 2001,7(6): 533-539.